Characterization of Macroprolactinemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00436111|
Recruitment Status : Completed
First Posted : February 16, 2007
Last Update Posted : February 16, 2007
The purpose of this study is to clarify the nature of macroprolactin which has recently been highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia. The results of this study are beneficial for the patients to whom unnecessary medications and unnecessary radiological examinations have been performed.
We used the remained serum samples taken for routine prolactin determination during the past several years. Since the blood was basically taken to examine the causes of hyperprolactinemia and only remained serum samples were used for this study, the Ethics Committee of Kobe City General Hospital judged that it was not required to obtain approval number.
|Condition or disease|
|Study Type :||Observational|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Study Start Date :||January 2005|
|Estimated Study Completion Date :||December 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00436111
|Kansai Medical University|
|Osaka, Japan, 570-8506|
|Study Chair:||Naoki Hattori, M.D., Ph.D.||Department of Pharmacology, Kansai Medical University|